What led you to a career in the deal-making industry?
I grew up in a family with several engineers, and that could have been an obvious path to follow, but I was keen to leverage my quantitative skillset towards business instead. I love learning about different industries, tracking the trends, understanding the market dynamics. Being part of a core team, working alongside our CEO partners to help transform their companies over time is what has really appealed to me about private equity.
Tell us about your experience and what was different during the Covid-19?
Prior to the pandemic, via several acquisitions, I helped build Maravai LifeSciences into a leading life sciences company providing critical products that enable the development of drug therapies, diagnostics, and novel vaccines. Recently, Maravai has emerged as a significant contributor to the COVID-19 response. Notably, Maravai’s CleanCap® technology is used to make mRNA vaccines, including the commercially approved Pfizer/BioNTech vaccine.
Recent most memorable deal I worked on....
In November 2020, and during the global pandemic, I helped prepare Maravai for its successful $1.9B IPO. The $1.9B of proceeds raised by Maravai in its IPO represented the 2nd largest financial sponsor healthcare IPO in 2020.
Luke joined GTCR in 2009 and became a Principal in 2020. Prior to joining GTCR, he worked in the investment banking division at Lehman Brothers and Barclays Capital. Luke holds an MBA with distinction from Harvard Business School and a BA magna cum laude in mathematics and economics from Kalamazoo College. Luke currently serves as a Director of Corza Health, Maravai LifeSciences and Regatta Medical. In addition, he played an instrumental role in GTCR’s past investment in Devicor Medical Products.
Education: MBA, Harvard Business School; BA, Kalamazoo College.
Location: GTCR, Chicago, IL, United States.